Scarica l'app Stockscreener
8.50
0.59%
0.05
Dopo l'orario di chiusura:
8.63
0.13
+1.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan
Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat
235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat
Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Keratoconus Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix - Barchart
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts - Inkl
Ocular Therapeutix announces over 300 subjects randomized in SOL-1 - Yahoo Finance
Ocular Pokes Ahead on Randomized Subjects - Baystreet.ca
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 - The Manila Times
Braidwell LP Has $19.49 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC's 10th Largest Position - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 29, 2024) - GuruFocus.com
Neuropathic Ocular Pain Market Is Booming Worldwide 2024-2031 | - openPR
Acuta Capital Partners LLC Cuts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 28, 2024) - GuruFocus.com
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock By Investing.com - Investing.com Canada
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com India
Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 By Investing.com - Investing.com Australia
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix chief scientific officer sells shares worth $26,561 - Investing.com
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Clinical Data at Major Healthcare Conferences in December - StockTitan
OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com
Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Hypertension Pipeline Forecast 2024: FDA Approvals, - openPR
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN
Ocular Therapeutix Q3 2024 Earnings Preview - MSN
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Ocular Therapeutix Posts Mixed Third Quarter 2024 Results - Vision Monday
Ocular Therapeutix: Q3 Earnings Snapshot - Houston Chronicle
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):